Genmab | GEN - Le Bénéfice D'Exploitation

Prix De L'Action
1,709.50
Variation Quotidienne
-1.50 -0.09%
Mensuellement
2.21%
Annuel
26.91%
Q2 Prévisions
1,628.53




Le Bénéfice D'Exploitation Changement Date
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.96B 464M 2025-12
argenx SE USD 371.14M 21.17M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bayer EUR 1.11B 1.65B 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Demant DKK 2.09B 224M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Fresenius Medical Care EUR 663M 213.06M 2025-12
Galapagos EUR 780.56M 822.23M 2025-12
Genmab DKK 260M 199M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
GN Store Nord DKK 570M 230M 2025-12
GRIFOLS EUR 275.38M 76.74M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Lonza CHF 673M 243M 2025-06
Merck EUR 474M 738M 2025-12
Novartis USD 4.06B 437M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
UCB EUR 1.29B 571M 2025-12